Blood pressure control with cilnidipine treatment in Japanese post-stroke hypertensive patients |
Molecule Updates
eMediNexus Coverage from: 
Blood pressure control with cilnidipine treatment in Japanese post-stroke hypertensive patients
eMediNexus,  26 February 2018
Coronavirus Live Count Map India

remove_red_eye 1428 Views
COVID-19 Vaccine Updates

#Cardiology #Nephrology

3 Read Comments                

Calcium channel blockers (CCBs) are the choice of therapy for post-stroke patients. A large-scale prospective study of 2667 post-stroke hypertensive patients treated with cilnidipine assessed BP control and adverse reactions in the patients. Cilnidipine treatment led to a reduction in both clinic and home BP 2 months after treatment initiation. The decreased BP was maintained until the end of 12 months of observation. The proportion of patients with well controlled clinic BP (<140/90 mmHg) rose from 21.5% to 65.3% with cilnidipine treatment, with no differences seen in effectiveness across the various clinical subtypes of stroke. In all, 346 adverse events occurred, with an overall incidence of 8.9% (238 of 2667 patients). Cilnidipine effectively treated uncontrolled BP and was well tolerated in post-stroke hypertensive patients in a real-world clinical setting. The results were published in Clinical and Experimental Hypertension.

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now